Comparing Tegoprazan 50 mg and Rabeprazole 20 mg for Preventing Upper Gastrointestinal Bleeding in Patients Using Blood Thinners
Led by Duk-Woo Park, MD · Updated on 2026-08-28
3320
Participants Needed
45
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are assessing the safety and effectiveness of a new drug called tegoprazan a Potassium-Competitive Acid Blocker, P-CAB compared to a standard proton pump inhibitor PPI, rabeprazole, in protecting the stomach and upper digestive tract from bleeding and ulcers. This study involves patients who have heart and vascular diseases and use blood-thinning medications that increase the risk of gastrointestinal GI bleeding. The goal is to determine if tegoprazan is at least as good as rabeprazole over a 12-month period.
The study has two main parts. First, a safety surveillance phase enrolls about 300 patients taking tegoprazan daily for six months to monitor for liver issues, increased stomach acid hormone levels, or infections. Then, the main randomized phase will include over 3,300 patients assigned to either tegoprazan 50 mg once daily with placebo rabeprazole or rabeprazole 20 mg once daily with placebo tegoprazan. Both groups will be followed for 12 months while taking their assigned medications.
Participants will be regularly checked for GI events like bleeding, ulcers, and stomach pain, as well as cardiovascular events such as heart attack or stroke. The study measures when these events first occur and tracks side effects. Safety is closely monitored through lab tests, symptoms, and medical imaging when needed. The entire trial spans several years, with participants involved for at least 12 months during treatment and follow-up.
CONDITIONS
Brief Title
Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy
Research Team
J
Jeong-youn Bae, RN
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patients aged 19 years or older with known cardiac or vascular disease
Receiving long-term antithrombotic therapy including antiplatelets, oral anticoagulants, or combinations
At high risk of gastrointestinal bleeding based on criteria such as age 65 or older, use of combined blood thinners, long-term NSAID or steroid use, history of GI bleeding or ulcers, or Helicobacter pylori infection
Willing to provide written informed consent
You will not qualify if you...
Active bleeding or bleeding disorders at the time of enrollment
Contraindications to antithrombotic therapies
Use of proton pump inhibitors or P-CAB within 4 weeks before randomization
Hemodynamically unstable conditions such as cardiogenic shock or severe heart failure
Severe anemia (hemoglobin below 8 g/dL) or recent blood transfusion
Severe thrombocytopenia (platelet count below 50,000/mm3)
Kidney failure requiring dialysis or very low kidney function
Severe chronic liver disease
Allergies or contraindications to study drugs or related compounds
Use of certain antibiotics or medications that interact with study drugs
Significant lab abnormalities or suspected cancer
Life expectancy less than 12 months due to other illnesses
Current treatment for Helicobacter pylori infection
Pregnancy, breastfeeding, or lack of effective birth control in women of childbearing potential
Participation in another clinical trial within 12 months except under specific exceptions
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Safety Surveillance Phase
Duration - 6 months
Approximately 300 patients take tegoprazan 50 mg once daily for 6 months to monitor safety, including liver function and infections.
Regular visits during 6 months
Randomized Treatment Phase
Duration - 12 months
Participants are randomly assigned to receive either tegoprazan or rabeprazole daily with matching placebo tablets, followed for 12 months to monitor gastrointestinal and cardiovascular events.
Regular visits throughout 12 months
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Comparing 24-Month Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent Placement in Patients With High Lipoproteina Levels
Evaluation of a 10-Minute Cardiovascular Magnetic Resonance Protocol for Diagnosing Cardiac Diseases Including Coronary Artery Disease and Cardiomyopathies
Study of Adults With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Tracking Heart and Health Outcomes Over Time
Study of Implantable Cardioverter Defibrillator Benefits in Adults with Coronary Artery Disease and Ventricular Fibrillation After Complete Revascularization
Randomized Double-Blind Study Evaluating Intravenous YN001 Versus Placebo in Adults With Coronary Atherosclerosis Receiving Cardiovascular Risk Therapy
Evaluating a Combined Polypill Strategy Versus Standard Medication for Patients After Acute Coronary Syndromes in a Multicenter Randomized Trial
Validating the ABCD-GENE Score to Identify Stable Coronary Artery Disease Patients Undergoing Elective PCI at Risk of Heart Injury During Procedure
Real-World Registry of Quantitative Flow Ratio-Guided Coronary Revascularization and Quality Evaluation Across Multiple Centers in China
Evaluation of Ischemia Using SandboxAQ Magnetocardiography Device in Adults Undergoing Angiography or Revascularization
Evaluating Coronary CT Angiography to Guide Calcium Modification Compared to Intravascular Ultrasound in Treating Calcified Coronary Artery Disease A Multicenter Randomized Trial
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Potassium-competitive acid blocker vs proton-pump inhibitor in patients receiving antithrombotic therapy who are at high risk for gastrointestinal bleeding: Rationale and design of the randomized PROTECT- HBR trial.